PMID- 25876794
OWN - NLM
STAT- MEDLINE
DCOM- 20160517
LR  - 20211203
IS  - 1600-0625 (Electronic)
IS  - 0906-6705 (Linking)
VI  - 24
IP  - 8
DP  - 2015 Aug
TI  - Oligosaccharide modification by N-acetylglucosaminyltransferase-V in macrophages 
      are involved in pathogenesis of bleomycin-induced scleroderma.
PG  - 585-90
LID - 10.1111/exd.12730 [doi]
AB  - Oligosaccharide modification by N-acetylglucosaminyltransferase-V (GnT-V), which 
      catalyses the formation of beta1,6 GlcNAc (N-acetylglucosamine) branches on 
      N-glycans, is associated with various pathologies, such as cancer metastasis, 
      multiple sclerosis and liver fibrosis. In this study, we demonstrated the 
      involvement of GnT-V in the pathophysiology of scleroderma. High expression of 
      GnT-V was observed in infiltrating cells in skin section samples from systemic 
      and localized patients with scleroderma. Most of the infiltrating cells were T 
      cells and macrophages, most of which were CD163(+) M2 macrophages. To determine 
      the role of GnT-V in scleroderma, we next investigated skin sclerosis in GnT-V 
      knockout (MGAT5(-/-) ) mice. Expression of GnT-V was also elevated in bleomycin 
      (BLM)-injected sclerotic skin, and MGAT5(-/-) mice were resistant to BLM-induced 
      skin sclerosis with reduced collagen type 1 alpha1 content, suggesting the biological 
      significance of GnT-V in skin sclerosis. Furthermore, the number of CD163(+) M2 
      macrophages and CD3-positive T cells in BLM-induced skin sclerosis was 
      significantly fewer in MGAT5(-/-) mice. In bone marrow-derived macrophages 
      (BMDMs), IL-4-induced expressions of Fizz1 and Ym1 were significantly reduced in 
      MGAT5(-/-) mice-derived BMDMs. Taken together, these results suggest the 
      induction of GnT-V in skin sclerosis progression is possibly dependent on 
      increased numbers of M2 macrophages in the skin, which are important for tissue 
      fibrosis and remodelling.
CI  - (c) 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Kato, Arisa
AU  - Kato A
AD  - Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, 
      Osaka, Japan.
AD  - Department of Molecular Biochemistry and Clinical Investigation, Graduate School 
      of Medicine, Osaka University, Suita, Osaka, Japan.
FAU - Yutani, Mizuki
AU  - Yutani M
AD  - Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, 
      Osaka, Japan.
AD  - Department of Molecular Biochemistry and Clinical Investigation, Graduate School 
      of Medicine, Osaka University, Suita, Osaka, Japan.
FAU - Terao, Mika
AU  - Terao M
AD  - Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, 
      Osaka, Japan.
FAU - Kimura, Akihiro
AU  - Kimura A
AD  - Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, 
      Osaka, Japan.
AD  - Department of Molecular Biochemistry and Clinical Investigation, Graduate School 
      of Medicine, Osaka University, Suita, Osaka, Japan.
FAU - Itoi, Saori
AU  - Itoi S
AD  - Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, 
      Osaka, Japan.
FAU - Murota, Hiroyuki
AU  - Murota H
AD  - Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, 
      Osaka, Japan.
FAU - Miyoshi, Eiji
AU  - Miyoshi E
AD  - Department of Molecular Biochemistry and Clinical Investigation, Graduate School 
      of Medicine, Osaka University, Suita, Osaka, Japan.
FAU - Katayama, Ichiro
AU  - Katayama I
AD  - Department of Dermatology, Graduate School of Medicine, Osaka University, Suita, 
      Osaka, Japan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150526
PL  - Denmark
TA  - Exp Dermatol
JT  - Experimental dermatology
JID - 9301549
RN  - 0 (Antigens, CD)
RN  - 0 (Antigens, Differentiation, Myelomonocytic)
RN  - 0 (CD163 antigen)
RN  - 0 (CD3 Complex)
RN  - 0 (Collagen Type I)
RN  - 0 (Collagen Type I, alpha 1 Chain)
RN  - 0 (Cytokines)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (Lectins)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (Retnla protein, mouse)
RN  - 11056-06-7 (Bleomycin)
RN  - 207137-56-2 (Interleukin-4)
RN  - EC 2.4.1.- (Mgat5 protein, human)
RN  - EC 2.4.1.- (N-Acetylglucosaminyltransferases)
RN  - EC 2.4.1.155 (alpha-1,6-mannosylglycoprotein beta 
      1,6-N-acetylglucosaminyltransferase)
RN  - EC 3.2.1.52 (Chil3 protein, mouse)
RN  - EC 3.2.1.52 (beta-N-Acetylhexosaminidases)
SB  - IM
CIN - Exp Dermatol. 2015 Aug;24(8):576-8. PMID: 25869115
MH  - Animals
MH  - Antigens, CD/analysis
MH  - Antigens, Differentiation, Myelomonocytic/analysis
MH  - Bleomycin/*toxicity
MH  - CD3 Complex/analysis
MH  - Collagen Type I/deficiency
MH  - Collagen Type I, alpha 1 Chain
MH  - Cytokines/pharmacology
MH  - Humans
MH  - Intercellular Signaling Peptides and Proteins/biosynthesis/genetics
MH  - Interleukin-4/pharmacology
MH  - Lectins/biosynthesis/genetics
MH  - Macrophages/chemistry/drug effects/enzymology
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Mice, Knockout
MH  - N-Acetylglucosaminyltransferases/deficiency/genetics/*physiology
MH  - Receptors, Cell Surface/analysis
MH  - Scleroderma, Systemic/chemically induced/*enzymology/pathology
MH  - Sclerosis
MH  - Skin/enzymology/pathology
MH  - T-Lymphocyte Subsets/chemistry/enzymology
MH  - beta-N-Acetylhexosaminidases/biosynthesis/genetics
OTO - NOTNLM
OT  - N-acetylglucosaminyltransferase-V
OT  - bleomycin
OT  - localized scleroderma
OT  - macrophages
OT  - systemic sclerosis
EDAT- 2015/04/17 06:00
MHDA- 2016/05/18 06:00
CRDT- 2015/04/17 06:00
PHST- 2015/04/08 00:00 [accepted]
PHST- 2015/04/17 06:00 [entrez]
PHST- 2015/04/17 06:00 [pubmed]
PHST- 2016/05/18 06:00 [medline]
AID - 10.1111/exd.12730 [doi]
PST - ppublish
SO  - Exp Dermatol. 2015 Aug;24(8):585-90. doi: 10.1111/exd.12730. Epub 2015 May 26.